Hematological Indices and Sympathetic Block Response in Neuropathic Pain
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnkara City Hospital Bilkent
About this trial
This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Diagnosis of neuropathic pain based on clinical evaluation
DN4 and/or LANSS scores compatible with neuropathic pain
Undergoing sympathetic nerve block as part of routine clinical treatment
Disqualifiers
Age <18 years
Active infection or acute inflammatory disease
Active malignancy
History of hematological disease
Trial population
Adult patients diagnosed with neuropathic pain and undergoing sympathetic nerve block procedures in the Algology Clinic of Ankara Bilkent City Hospital.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
120 Participants
are grouped into 1 trial groupGroup A: Neuropathic Pain Cohort
Trial outcomes
Primary outcomes
1
Treatment Response at Month 3
Treatment response will be defined as achieving at least 50% reduction in Numeric Rating Scale (NRS) pain score compared with baseline. NRS 0 means = no pain NRS 10 means= worst pain imaginable
Time frame
3 th monthSecondary outcomes
1
NRS (Numeric Rating Scale Pain Score)
Change in pain intensity measured by the 0-10 Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Time frame
Baseline and 3rd month2
Change in Hematological Inflammatory Indices
Change in hematological inflammatory indices including NLR, PLR, MLR, SII, SIRI, AISI, and RDW from baseline to follow-up.
Time frame
Baseline and 3rd monnth3
GPE (Global Perceived Effect)
Patient-reported global improvement after treatment assessed using the Global Perceived Effect scale.Patient-reported overall improvement after treatment assessed using a 7-point Global Perceived Effect scale. Scale Description: 1. = completely recovered 2. = much improved 3. = slightly improved 4. = unchanged 5. = slightly worsened 6. = much worsened 7. = worse than ever Minimum Value: 1 Maximum Value: 7 Interpretation: Lower scores indicate better clinical improvement. Time Frame: Month 3
Time frame
3rd monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov